Patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions;
Have at least one measurable lesion according to RECIST 1.1 standards;
ECOG PS score: 0-2;
Expected survival greater than 3 months;
Routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy;
The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits;
Researchers believe treatment can benefit.
You may not be if
A proven allergy to the test drug and/or its excipients;
Pregnant or lactating women;
Patients judged by the investigator to be unsuitable for inclusion in this study;
Clareo Health | FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
